AstraZeneca PLC (AZN)vsZura Bio Limited Class A Ordinary Shares (ZURA)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
ZURA
Zura Bio Limited Class A Ordinary Shares
$5.08
+1.40%
HEALTHCARE · Cap: $502.87M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
ZURA
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for ZURA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : ZURA
ZURA has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : ZURA
The primary concerns for ZURA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 24/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Zura Bio Limited Class A Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Zura Bio Limited (Ticker: ZURA) is a forward-thinking biotechnology company focused on developing transformative therapies for autoimmune disorders and rare diseases. The company is poised for growth with a robust pipeline of innovative drug candidates, underscored by its commitment to rigorous clinical trials and cutting-edge research methodologies. Guided by an experienced management team and bolstered by strategic partnerships, Zura Bio is strategically positioned within the biopharmaceutical sector, presenting significant opportunities for institutional investors seeking exposure to advanced therapeutic solutions in an evolving marketplace.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?